RECOMBINATE 1000 IU
国: イスラエル
言語: 英語
ソース: Ministry of Health
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
COAGULATION FACTOR VIII RECOMBINANT 1000 IU/VIAL
から入手可能:
TEVA MEDICAL MARKETING LTD.
ATCコード:
B02BD02
医薬品形態:
POWDER FOR SOLUTION FOR INJECTION
投与経路:
I.V
製:
BAXTER S.A., BELGIUM
治療群:
COAGULATION FACTOR VIII
適応症:
The use of Recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Recombinate is also indicated in the perioperative management of patients with haemophilia A. Recombinate is appropriate for use in children of all ages including the newborn. (Safety and efficacy studies have been performed in both previously treated and previously untreated children). The product in not suitable for the treatment of von Willebrand's disease.
承認日:
2010-07-01
